Intravenous immune globulin (IVIG) is prescribed for Kawasaki disease primarily to?

Intravenous immune globulin (IVIG) is a key treatment for Kawasaki disease primarily because it helps prevent or reduce coronary artery damage. Kawasaki disease is characterized by inflammation of the blood vessels, particularly affecting the coronary arteries in children. Without prompt treatment, this inflammation can lead to serious complications, including coronary artery aneurysms and other cardiac issues.

The mechanism of IVIG in this context involves modulating the immune response and reducing inflammation, which lowers the risk of long-term cardiac damage. Early and appropriate administration of IVIG is associated with a decrease in the risk of coronary artery sequelae, which is the most significant concern in Kawasaki disease management.

While IVIG may have ancillary effects such as reducing fever and potentially improving overall well-being, its primary purpose in this particular setting is the protection of the coronary arteries from inflammatory damage. This role makes it a vital therapy for children diagnosed with Kawasaki disease.